The ASCO Post

About two in five women diagnosed with ovarian cancer were only diagnosed after an emergency admission to the hospital, according to the results of a national population-based study from England that was published in BMJ Oncology.

In a phase III trial (CAIRO6) reported in The Lancet Oncology, Rovers et al found that perioperative systemic therapy was not associated with significant improvement in overall survival vs surgery alone in patients with resectable peritoneal-only metastases of colorectal adenocarcinoma.

As reported in The Lancet Oncology by Mauritz et al, 10-year follow-up of a Dutch prospective registry study (RAPCHEM: BOOG 2010–03) indicated that tailoring postoperative locoregional radiotherapy based on nodal response to primary chemotherapy was associated with maintenance of a low locoregional recurrence rate in patients with cT1–2N1 breast cancer after primary systemic therapy.

Alcohol use and smoking were linked to breast cancer and atrial fibrillation/flutter in women aged 55 years and older in multiple regions of the world, according to new research published by Zhang et al in the Journal of the American Heart Association. Breast cancer and atrial fibrillation—also called AFib or irregular heartbeat—represent a growing global health burden, according to study authors. Why these conditions have similar rates in specific parts of the world is not well understood.

On July 10, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), each in combination with the NECTIN4-directed antibody-drug conjugate enfortumab vedotin-ejfv (Padcev), as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer (MIBC).

On July 9, the U.S. Food and Drug Administration (FDA) approved the anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications.

As reported in The Lancet Oncology by Francolini et al, an unplanned long-term analysis of overall survival in the Italian phase II ARTO trial showed a survival benefit with the addition of metastasis-directed therapy with stereotactic body radiotherapy (SBRT) to abiraterone acetate and androgen-deprivation therapy (ADT) in patients with oligometastatic castration-resistant prostate cancer.

In the long-term follow-up of a Japanese phase II/III trial (JCOG1008) reported in the Journal of Clinical Oncology, Tahara et al found maintained noninferiority of chemoradiotherapy with weekly vs every-3-week cisplatin for overall survival in patients with postoperative high-risk locally advanced squamous cell carcinoma of the head and neck.

In a Chinese phase II trial reported in the Journal of Clinical Oncology, Li et al found that the first-line combination of disitamab vedotin, tislelizumab, and S-1 was associated with high activity in patients with HER2-overexpressing advance gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Targeting BCL2 family proteins may counteract acquired resistance to BRAF and MEK inhibition in patients with BRAF-mutant metastatic melanoma, according to findings from a preclinical study published in Nature Communications.